Genetic Syndromes & Prostate Cancer: Hereditary Risk & Testing

What percentage of prostate cancer is hereditary?

Most prostate cancer is sporadic (occurs by chance). Approximately 5-10% of cases are hereditary, caused by inherited genetic mutations passed down through families.

Hereditary prostate cancer tends to:

• Occur at a younger age (<55 years)
• Be more aggressive (higher Gleason score)
• Cluster in families with other cancers (breast, ovarian, pancreatic, colon)

BRCA1 and BRCA2 – strongest link

BRCA1 and BRCA2 are tumour suppressor genes best known for their role in breast and ovarian cancer. They also significantly increase prostate cancer risk.

BRCA2 mutation (most significant):

• Risk: 5-8x increased risk of prostate cancer
• Aggressiveness: More aggressive cancer (higher Gleason score, higher stage)
• Age: Earlier age at diagnosis (often <65)
• Prognosis: Worse outcomes than non-carriers
• Prevalence: 1-2% of men with prostate cancer (higher in metastatic disease)

BRCA1 mutation:

• Risk: 2-3x increased risk (less than BRCA2)
• Aggressiveness: Also associated with more aggressive cancer

Screening recommendations for carriers:

• Start PSA screening at age 40 (instead of 45-50)
• Annual PSA and DRE
• Consider baseline MRI at age 40-45

HOXB13 mutation – early-onset prostate cancer

HOXB13 is a homeobox gene involved in prostate development. The G84E mutation is associated with early-onset prostate cancer.

• Risk: 3-5x increased risk
• Age: Early-onset (<55 years)
• Prevalence: Rare (1-2% of hereditary cases)
• Population: More common in men of European descent

Screening recommendations:

• Start PSA screening at age 40-45
• Annual PSA and DRE

Lynch syndrome – increased risk of multiple cancers

Lynch syndrome (hereditary non-polyposis colorectal cancer – HNPCC) is caused by mutations in mismatch repair genes (MLH1, MSH2, MSH6, PMS2, EPCAM).

• Prostate cancer risk: 2-3x increased risk
• Other cancers: Colorectal, endometrial, ovarian, gastric, urinary tract
• Age: Earlier onset than sporadic cancer
• Aggressiveness: Some studies suggest more aggressive

Screening recommendations:

• Start PSA screening at age 40
• Annual PSA and DRE
• Consider MRI if PSA rises

ATM, CHEK2, PALB2 – moderate-risk genes

ATM:

• Risk: 2-3x increased risk
• Other cancers: Breast, pancreatic
• Aggressiveness: Associated with aggressive disease

CHEK2:

• Risk: 2-3x increased risk
• Other cancers: Breast, colorectal

PALB2:

• Risk: 2-3x increased risk (partner of BRCA2)
• Other cancers: Breast, pancreatic

Screening recommendations:

• Start PSA screening at age 40-45
• Annual PSA and DRE

Other genes – NBN, MSH2, MSH6, PMS2

• NBN (NBS1): 2-3x increased risk; rare
• MSH2, MSH6, PMS2: Lynch syndrome genes (see above)
• EPCAM: Lynch syndrome gene
• RAD51C, RAD51D: Rare, moderate risk
• BRIP1, FANCA, FANCL, FANCM: Rare, limited evidence

Who should get genetic testing? – NCCN guidelines

Genetic testing is recommended for men with prostate cancer who meet any of the following criteria (NCCN 2025):

• Metastatic prostate cancer (any age) – strongest indication
• High-risk or very high-risk localized prostate cancer (any age)
• Intraductal or cribriform histology on biopsy
• Ashkenazi Jewish ancestry with prostate cancer
• Family history:
  • Two or more first-degree relatives with prostate cancer (any age)
  • One first-degree relative with prostate cancer diagnosed at age <60
  • Family history of BRCA-related cancers (breast, ovarian, pancreatic)

Testing for unaffected men:

• Men with a known family history of a hereditary cancer syndrome
• Men with a first-degree relative with a known mutation (BRCA, HOXB13, etc.)

Clinical implications – screening and treatment

Implications for screening (carriers):

• BRCA2: Start PSA at age 40, annual, consider baseline MRI
• BRCA1, HOXB13, Lynch syndrome: Start PSA at age 40-45
• ATM, CHEK2, PALB2: Start PSA at age 40-45

Implications for treatment (men diagnosed with prostate cancer):

• PARP inhibitors (olaparib, rucaparib, niraparib): Approved for men with BRCA1/2, ATM, PALB2, and other HRR gene mutations in metastatic castration-resistant prostate cancer (mCRPC)
• Response rate: 40-50% in BRCA-mutated mCRPC
• Testing recommended: All men with metastatic prostate cancer should have genetic testing (tumour or germline)

Interactive FAQ – Genetic syndromes and prostate cancer

---

Disclaimer: This information is for educational purposes and intended for clinicians and researchers. Genetic testing should be accompanied by genetic counselling.